FOX Business: CEO of synthetic biotech company Absci on Nasdaq debut

Jul 22, 2021

Absci CEO and Founder Sean McClain explains his company’s outlook and his experience going public via an IPO. Read more.

Related Media Highlights

Related Resources

Absci R&D Day 2024

Read More

NeurIPS 2024

Read More

Development of ABS-101: A potential best-in-class anti-TL1A antibody for the treatment of IBD

Read More